Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Duchenne Group's Presentation Is Milestone For Patient Involvement

Executive Summary

Advocacy group gets portion of Sarepta's formal presentation period to present eteplirsen patient experience data, believed to be a first for an advisory committee meeting. Will it become commonplace?

Advertisement

Related Content

US FDA Planning Another Patient Group To Boost Involvement
Eteplirsen Revisited? FDA Panel To Weigh Protocol Changes For Two Sarepta Drugs
US FDA Patient Affairs Office Could Accelerate Involvement With 'Central Entry Point'
Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review
US FDA Has Slim Advisory Committee Schedule – A Sign Of Things Not To Come?
Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Patient-Driven Drug Development Requires New Transparency Policies
Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups
PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up
FDA Quietly Consults Patients To Understand Vimizim's Six-Minute Walk Significance

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057609

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel